{"id":"NCT00185211","sponsor":"Bayer","briefTitle":"BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study","officialTitle":"Open-label, Multi-center Phase III Extension of the Double-blind, Placebo-controlled BENEFIT Study (no. 92012/304747) to Obtain Long-term Follow-up Data of Patients With Clinically Definite Multiple Sclerosis (MS) and Patients With a First Demyelinating Event Suggestive of MS Treated With 8 MIU (250 µg) Interferon Beta-1b (Betaferon® / Betaseron®) Given Subcutaneously Every Other Day for at Least 36 Months.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2002-08","primaryCompletion":"2008-05","completion":"2008-05","firstPosted":"2005-09-16","resultsPosted":"2010-11-30","lastUpdate":"2013-12-30"},"enrollment":468,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Sclerosis"],"interventions":[{"type":"DRUG","name":"Interferon beta-1b (Betaseron, BAY86-5046)","otherNames":[]},{"type":"DRUG","name":"Interferon beta-1b (Betaseron, BAY86-5046)","otherNames":[]}],"arms":[{"label":"Initial IFNB-1b (Interferon beta-1b)","type":"EXPERIMENTAL"},{"label":"Initial Placebo","type":"EXPERIMENTAL"}],"summary":"This study will primarily compare the long-term effects of an early and continued treatment with Betaferon/Betaseron (patients who were treated with active medication during the double-blind BENEFIT study) to treatment initiated either after Clinically Definite Multiple Sclerosis (CDMS) has been diagnosed or after two years (those patients who were treated with placebo during the double-blind BENEFIT study).\n\nAnalyses are based on the integrated data of the initial BENEFIT study and this follow-up study.","primaryOutcome":{"measure":"Time to Clinically Definite Multiple Sclerosis (CDMS) Represented by Kaplan-Meier Estimates of the Cumulative Percentage of Participants With CDMS at Selected Points in Time","timeFrame":"up to 60 months after start of treatment","effectByArm":[{"arm":"Initial IFNB-1b (Interferon Beta-1b)","deltaMin":26.9,"sd":null},{"arm":"Initial Placebo","deltaMin":45,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0027"},{"comp":"OG000 vs OG001","p":"0.0028"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":94,"countries":["Austria","Belgium","Canada","Czechia","Denmark","Finland","France","Germany","Hungary","Israel","Italy","Netherlands","Norway","Poland","Portugal","Slovenia","Spain","Sweden","Switzerland","United Kingdom"]},"refs":{"pmids":["24218527","23842212","22492127","19748319","21849647","22183938","21795647","19901165","18004635","22541587","19457248","17846268","17679016","19879194"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":61,"n":292},"commonTop":["Flu syndrome","Injection site reaction","Multiple sclerosis","Upper respiratory infection","Headache"]}}